This post was originally published on this site The Alzheimer’s Association estimates that nearly 5.8 million people in the United States have the condition. Most people who are diagnosed with Alzheimer’s disease are 65 or older, but the disease is found across all age groups, including 200,000 with an early-onset diagnosis. The adage that “there’s…
This post was originally published on this site To enable researchers to study prospective links between sleep and dementia, a cutting-edge sleep unit has opened at the University of East Anglia (UEA) in Norwich, England. While sleeping issues commonly occur in dementia, it’s unclear whether diseases such as Alzheimer’s cause the disturbances, or whether problems sleeping…
This post was originally published on this site A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the safety, tolerability, and pharmacokinetics (the movement of a medicine into, through, and out of the body) of ascending…
This post was originally published on this site Caring for someone with Alzheimer’s disease is much more challenging than most people realize. The stress of taking over a dementia patient’s financial and personal responsibilities, as well as managing their care is exhausting. During the later stages of the disease, patients with dementia need continual help…
This post was originally published on this site The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers,…
This post was originally published on this site Alzheimer’s disease is cruel. And its cruelty is unparalleled, robbing patients and stripping entire families of what they hold dearest. Definite characteristics are associated with this mind-altering condition, one of which is an unfortunate outcome. But if you’re in the throes of the disease, you already know…
This post was originally published on this site Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E). The findings…
This post was originally published on this site United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer’s disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial are now eligible to enroll in a long-term follow-up study that will continue to assess the vaccine’s safety…
This post was originally published on this site Preliminary data from a Phase 2 study suggests that treating early Alzheimer’s disease patients who are positive for herpes simplex virus with an antiviral medicine may help halt their cognitive decline. Hugo Lövheim, MD, PhD, at Umeå University, Sweden, presented the results in a presentation titled “Valz…
This post was originally published on this site AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer’s dementia, according to preliminary data from a worldwide Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate was designed as a second-generation version of Nuedexta, a two-drug combo approved for pseudobulbar affect. AVP-786 is…
